Oxygenta Pharmaceutical Limited - Company Profile

It is a chemicals and materials public limited company based in Medak, Telangana, India, established in 1990.
1990 Medak, Telangana, India Active
Last Updated:
Access Report
About Oxygenta Pharmaceutical Limited

Oxygenta Pharmaceutical Limited, a active public limited company, was established on 27 November 1990 in Medak, Telangana, India. Engaging in organic chemicals & compounds within the manufacturing sector, it holds CIN: L24110TG1990PLC012038. Registered under ROC Roc Hyderabad. it is listed on BSE: 524636. It has an authorized capital of ₹37.50 Cr and a paid-up capital of ₹36.98 Cr.

Formerly known as S.S. Organics Pvt Ltd, S.S. Organics Ltd.. It upholds a compliant status. Employing 98 professional, Its leadership includes Vedavathi Gangavaram (Director), Chandra Mouliswar Reddy Gangavaram (Whole-Time Director), Sidda Reddy Kanuparthi (Director). Past directors included Gangi Reddy Narravula, Vedavathi Gangavaram, Chandra Mouliswar Reddy Gangavaram. It holds ₹46.60 Cr open charges and ₹55.70 Cr settled loans. Its latest AGM occurred on 19 September 2025, with the balance sheet filed on 31 March 2025. It is based at Survey No.252/1,Aroor Village,Sadasivapet Mandal, Medak District,, Medak, Telangana.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    L24110TG1990PLC012038

  • Registration Number

    012038

  • Incorporation Date

    27 November 1990

  • Authorized Capital

    ₹37.50 Cr

  • Paid-Up Capital

    ₹36.98 Cr

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Listed (BSE: 524636)

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 37.50 Cr
  • Paid Up Capital ₹ 36.98 Cr
  • Company Age 35 Year, 3 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 46.60 Cr
  • Satisfied Charges ₹ 55.70 Cr
  • Revenue Growth **** -48.78%
  • Profit Growth **** -1795.44%
  • Ebitda **** -582.17%
  • Net Worth -33.41%
  • Total Assets **** 74.06%
Company report

Oxygenta Pharmaceutical Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Oxygenta Pharmaceutical Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Oxygenta Pharmaceutical Limited?
Current Directors
Name Designation Appointment Date Status
Vedavathi Gangavaram Director 20 Jun 2025 Current
Chandra Mouliswar Reddy Gangavaram Whole-Time Director 20 Jun 2025 Current
Sidda Reddy Kanuparthi Director 20 Jun 2025 Current
Balasubba Reddy Mamilla Whole-Time Director 20 Jun 2025 Current
Veera Reddy Arava Director 20 Jun 2025 Current
Sharvari Swapnil Shinde Director 20 Jun 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 04 Sep 2023 Past
Pramod Abcsdd Additional Director 18 Sep 2025 Past
Pramod Abcsdd Additional Director 18 Sep 2025 Past
Pramod Abcsdd Director 20 Jun 2017 Past
Pramod Abcsdd Director 06 Dec 2021 Past
Pramod Abcsdd Director 27 Feb 2017 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Oxygenta Pharmaceutical.

Oxygenta Pharmaceutical Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 48.78% decrease. The company also saw a substantial fall in profitability, with a 1795.44% decrease in profit. The company's net worth observed a substantial decline by a decrease of 33.41%.

Oxygenta Pharmaceutical revenue growth over time
Oxygenta Pharmaceutical profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -48.78%
*******
*******
*******
*******
Revenue from Operations
*******
 -48.80%
*******
*******
*******
*******
Total Assets
*******
 74.06%
*******
*******
*******
*******
Profit or Loss
*******
 -1795.44%
*******
*******
*******
*******
Net Worth
*******
 -33.41%
*******
*******
*******
*******
EBITDA
*******
 -582.17%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Oxygenta Pharmaceutical?

In 2023, Oxygenta Pharmaceutical had a promoter holding of 8.99% and a public holding of 91.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹466,000,000.00

Satisfied Charges

₹557,000,000.00

Charges Breakdown by Lending Institutions
  • Others : 46.60 Cr
Latest Charge Details
Date Lender Amount Status
30 Jun 2025 Others ₹46.60 Cr Open
02 Sep 2022 Others ₹5.00 Cr Satisfied
02 Sep 2022 Others ₹10.00 Cr Satisfied
21 Dec 2020 Others ₹6.70 Cr Satisfied
10 Sep 2020 Others ₹31.50 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Oxygenta Pharmaceutical?

Oxygenta Pharmaceutical has a workforce of 98 employees as of Sep 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Oxygenta Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oxygenta Pharmaceutical's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Oxygenta Pharmaceutical
Recent Activity within the Organization
  • Director Appointment

    The activity Prasad Reddy Battinapatla was appointed as a Cfo was appointed as a Cfo on 02 Dec 2025 & has been associated with this company since 2 months 28 days . was completed.

  • Charges

    The activity A charge registered on 10 Sep 2020 via Charge ID 100377137 with Others was fully satisfied on 26 Nov 2025. was completed.

  • Charges

    Progress on A charge with Others of Rs. 46.60 Cr registered on 30 Jun 2025 with Charge ID 101130641 was modified on 30 Sep 2025. was documented.

  • Annual General Meeting

    Progress on Oxygenta Pharmaceutical Limited last Annual general meeting of members was held on 19 Sep 2025 as per latest MCA records. was documented.

  • Director Appointment

    Progress on Kumkum Bajaj was appointed as a Company Secretary was appointed as a Company Secretary on 12 Sep 2025 & has been associated with this company since 5 months 17 days . was documented.

  • Charges

    A charge registered on 02 Sep 2022 via Charge ID 100607294 with Others was fully satisfied on 07 Aug 2025. was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Oxygenta Pharmaceutical Limited?

The CIN of Oxygenta Pharmaceutical Limited is L24110TG1990PLC012038.

Where is Oxygenta Pharmaceutical Limited headquartered?

Oxygenta Pharmaceutical Limited is headquartered at Survey No.252/1,Aroor Village,Sadasivapet Mandal, Medak District,, Medak, Telangana.

When was Oxygenta Pharmaceutical Limited incorporated?

Oxygenta Pharmaceutical Limited was incorporated on 27 November 1990.

Who are the current directors of Oxygenta Pharmaceutical Limited?

The current directors of Oxygenta Pharmaceutical Limited are

What is the primary industry of Oxygenta Pharmaceutical Limited?

The primary industry of Oxygenta Pharmaceutical Limited is Manufacturing.

Is Oxygenta Pharmaceutical Limited a listed company?

Oxygenta Pharmaceutical Limited is listed. It is listed on BSE: 524636.

What is the capital structure of Oxygenta Pharmaceutical Limited?

The authorized capital of Oxygenta Pharmaceutical Limited is ₹37.50 Cr, and the paid-up capital is ₹36.98 Cr.

What is the compliance status of Oxygenta Pharmaceutical Limited?

The compliance status of Oxygenta Pharmaceutical Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available